Surface Oncology, Inc.

DB:QSOA Stock Report

Market Cap: €60.8m

Surface Oncology Management

Management criteria checks 3/4

Surface Oncology's CEO is Rob Ross, appointed in Apr 2021, has a tenure of 2.42 years. total yearly compensation is $1.92M, comprised of 29.5% salary and 70.5% bonuses, including company stock and options. directly owns 0.14% of the company’s shares, worth €83.21K. The average tenure of the management team and the board of directors is 2.4 years and 4.7 years respectively.

Key information

Rob Ross

Chief executive officer

US$1.9m

Total compensation

CEO salary percentage29.5%
CEO tenure2.4yrs
CEO ownership0.1%
Management average tenure2.4yrs
Board average tenure4.7yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Rob Ross's remuneration changed compared to Surface Oncology's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2023n/an/a

-US$93m

Mar 31 2023n/an/a

-US$90m

Dec 31 2022US$2mUS$568k

-US$64m

Sep 30 2022n/an/a

-US$66m

Jun 30 2022n/an/a

-US$63m

Mar 31 2022n/an/a

-US$57m

Dec 31 2021US$5mUS$506k

-US$78m

Sep 30 2021n/an/a

US$13m

Jun 30 2021n/an/a

US$17m

Mar 31 2021n/an/a

US$21m

Dec 31 2020US$1mUS$435k

US$59m

Sep 30 2020n/an/a

-US$24m

Jun 30 2020n/an/a

-US$25m

Mar 31 2020n/an/a

-US$28m

Dec 31 2019US$810kUS$400k

-US$55m

Sep 30 2019n/an/a

-US$44m

Jun 30 2019n/an/a

-US$44m

Mar 31 2019n/an/a

-US$35m

Dec 31 2018US$880kUS$361k

-US$7m

Sep 30 2018n/an/a

-US$18m

Jun 30 2018n/an/a

-US$15m

Mar 31 2018n/an/a

-US$13m

Dec 31 2017US$467kUS$329k

-US$45m

Compensation vs Market: Rob's total compensation ($USD1.92M) is above average for companies of similar size in the German market ($USD418.12K).

Compensation vs Earnings: Rob's compensation has been consistent with company performance over the past year.

CEO

Rob Ross (49 yo)

2.4yrs

Tenure

US$1,924,455

Compensation

Dr. Robert W. Ross, also known as Rob, M.D., is President, Chief Executive Officer and Director at Surface Oncology, Inc since April 01, 2021. He serves as Independent Director at Xilio Therapeutics, Inc....

Leadership Team

NamePositionTenureCompensationOwnership
Robert Ross
President2.4yrsUS$1.92m0.14%
€ 83.2k
Alison O'Neill
Chief Medical Officer3.6yrsUS$1.06mno data
Jessica Fees
CFO & Treasurer4.8yrsno data0.17%
€ 101.9k
Chandra Adams
Deputy General Counsel & Secretaryless than a yearno data0.051%
€ 30.9k
Lisa McGrath
Chief People Officerno datano datano data
Shannon Devens
Senior Vice President of Development Operations1.8yrsno datano data

2.4yrs

Average Tenure

52yo

Average Age

Experienced Management: QSOA's management team is considered experienced (2.4 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Robert Ross
President2.4yrsUS$1.92m0.14%
€ 83.2k
Charles Sigal
Independent Member of Scientific Advisory Board & Director5.6yrsUS$80.57k0.075%
€ 45.5k
David Grayzel
Independent Director9.4yrsUS$84.57k0%
€ 0
J. Goater
Director5.6yrsUS$72.57k0.21%
€ 129.2k
Alexander Rudensky
Member of Scientific Advisory Board4.7yrsno datano data
Armen Shanafelt
Independent Director8.8yrsUS$89.07k0%
€ 0
Laurie Stelzer
Independent Director5.6yrsUS$92.57k0%
€ 0
F. Hodi
Member of Scientific Advisory Boardno datano datano data
Denice Torres
Independent Chairman & Lead Independent Director2.2yrsUS$151.82k0%
€ 0
Christopher Hunter
Member of Scientific Advisory Board4.7yrsno datano data
Carla Rothlin
Member of Scientific Advisory Board4.7yrsno datano data
Arlene Sharpe
Member of Scientific Advisory Board4.7yrsno datano data

4.7yrs

Average Tenure

55yo

Average Age

Experienced Board: QSOA's board of directors are considered experienced (4.7 years average tenure).